Register Now for the 3rd Annual EHE Virtual 5K Run/Walk!
Mark your calendars for the last week of April, 2018! Registration is now open for the 3rd Annual EHE Virtual 5K Run/Walk and will end April 1st.
This 5K is for all ages and abilities. It is also “virtual,” which means it can be done anywhere you are. We simply ask you finish the 3.1 miles by running or walking (or any other form of exercise) any time between April 23rd-30th. You can do it alone or with others who register.
The price of $26 includes a t-shirt (+$3 for larger sizes), race bib, EHE bracelet, and temporary tattoo. These items will be shipped mid-April and arrive by April 23rd.
Last year we had over 500 participants. Our goal is to top last year’s total by registering over 600 participants in 2018. Last year many small groups of families and friends joined together in neighborhoods, parks, or local trails all over the nation to participate in this virtual event and support or honor their loves ones. We also had many individuals complete this event on their own at a location/time convenient for them. We hope you will join us in this fun event.
Don’t forget to like and share our event on Facebook!
We hope you will share pictures of your 5K and show us who you are supporting.
Information, Community and Research Funding
The mission of The EHE Foundation is to seek treatments and a cure for Epithelioid Hemangioendothelioma (EHE) by increasing awareness, pursuing scientific research, advocating for and supporting EHE patients, and bridging information between researchers, providers and patients.
HOW TO FIGHT EHE
IMPORTANT EHE NEWS & TRIALS
The Pledge, Edition 11
We warmly welcome all our readers to this eleventh edition of “The Pledge”, the quarterly newsletter of the EHE Group. We hope you enjoy this newsletter, covering the fourth quarter of 2017.
Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That Is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery.
ClinicalTrials.gov Identifier: NCT03148275
For the last several years Dr.Brian Rubin has been working on unlocking genetic driving mechanism behind EHE progression. His work resulted in identification of a pathway directly involved in supporting of EHE genetic malfunction. During the Lab experiments, Dr Rubin was able to disrupt this pathway with MEK inhibitor.
The clinical trial uses MEK inhibitor Mekinist. The purpose of the study to verify that what Dr.Rubin observed in his Lab actually translates in clinical effect in EHE patients. It is a multi institutional study which makes it very easy for enrollment in different parts of the country. You can see more information using following link.
FAQs for P10015, SARC033 – Phase II trial of trametinib in patients with unresectable or metastatic epithelioid hemangioendothelioma (EHE). Is there a point at ...
Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)
ClinicalTrials.gov Identifier: NCT03331250
This research study is studying a drug as a possible treatment for Angiosarcoma or Epithelioid hemangioendothelioma (EHE).
-The drug involved in this study is Eribulin
In this research study, the investigators are studying how safe and effective eribulin is in participants with Angiosarcoma or EHE.
Eribulin was created to mimic the structure of a chemical that is released from a sea sponge. The investigators believe that this drug has anti-cancer effects on tumors by blocking proteins called microtubules, among other functions. It may work by preventing the cancer cells from dividing and eventually cause the tumor cells to die similar to other drugs that target microtubules